ReviewBritish journal of pharmacology2009
Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.
Review in British journal of pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Nanotechnology advances for psoriasis treatment and future prospects.Discover nano · 2026Review
- Exploring the potential of nanomedicine for gene therapy across the physicochemical and cellular barriers.Functional & integrative genomics · 2024Review
- Development and application of ribonucleic acid therapy strategies against COVID-19.International journal of biological sciences · 2022Review
- The development and improvement of ribonucleic acid therapy strategies.Molecular therapy. Nucleic acids · 2021Review
- Systematic Combination of Oligonucleotides and Synthetic Polymers for Advanced Therapeutic Applications.Macromolecular research · 2021Review
- Molecular and Coarse-Grained Modeling to Characterize and Optimize Dendrimer-Based Nanocarriers for Short Interfering RNA Delivery.ACS omega · 2020Article
- Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment.International journal of molecular sciences · 2019Review
- Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides.Drug delivery · 2017Review
- Enhancing the Therapeutic Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation.Molecules (Basel, Switzerland) · 2017Review
- Encapsulation of nor-β-lapachone into poly(d,l)-lactide-MedChemComm · 2017Article
- Anti-microRNA-21/221 and microRNA-199a transfected by ultrasound microbubbles induces the apoptosis of human hepatoma HepG2 cells.Oncology letters · 2017Article
- Nano-ART and NeuroAIDS.Drug delivery and translational research · 2016Review
- Controlled Release of Nor-β-lapachone by PLGA Microparticles: A Strategy for Improving Cytotoxicity against Prostate Cancer Cells.Molecules (Basel, Switzerland) · 2016Article
- Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy.ACS nano · 2015Article
- miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents.Future medicinal chemistry · 2014Review
- Dendrimers as carriers for siRNA delivery and gene silencing: a review.TheScientificWorldJournal · 2013Review
- A polyethylenimine-linoleic acid conjugate for antisense oligonucleotide delivery.BioMed research international · 2013Article
- Canonical and non-canonical barriers facing antimiR cancer therapeutics.Current medicinal chemistry · 2013Review
- Nanotechnology and the treatment of HIV infection.Viruses · 2012Review
- Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells.Cancer letters · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antisense oligonucleotides and small interfering RNA have enormous potential for the treatment of a number of diseases, including cancer. However, several impediments to their widespread use as drugs still have to be overcome: in particular their lack of stability in physiological fluids and their poor penetration into cells. Association with or encapsulation within nano- and microsized drug delivery systems could help to solve these problems. In this review, we describe the progress that has been made using delivery systems composed of natural or synthetic polymers in the form of complexes, nanoparticles or microparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.